Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trimebutine 3-thiocarbamoylbenzenesulfonate
- Development stage
- Phase 2
- Lead developer
- gicare Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GIC-1001 (trimebutine 3-thiocarbamoylbenzenesulfonate) is an orally administered, peripherally acting opioid agonist and hydrogen sulfide (H2S) donor developed by gIcare Pharma. It is designed to provide colonic analgesia and reduce spasms during procedures such as colonoscopy, potentially allowing for sedation-free examinations. The molecule is a novel salt of trimebutine, a known modulator of gastrointestinal motility and visceral sensitivity, combined with a 3-thiocarbamoylbenzenesulfonate moiety that releases H2S to enhance antinociceptive effects. Clinical development has primarily targeted visceral pain management in colonoscopy and irritable bowel syndrome (IBS).
- Brand names
- Newbutin SRNewbutin
- Other names
- GIC-1001GIC1001GIC 1001trimebutine 3-thiocarbamoylbenzenesulfonatetrimebutine3-thiocarbamoylbenzenesulfonatetrimebutine-3-thiocarbamoylbenzenesulfonate
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on trimebutine 3-thiocarbamoylbenzenesulfonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trimebutine 3-thiocarbamoylbenzenesulfonate.